The Patient Experience of Drug Side Effects in Rheumatoid Arthritis: Intriguing Data From an Exploratory Online Survey

Davis, John M.

doi:10.3899/jrheum.220412

Cited by 5 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, since the treatment of RA is a long-term process, the side effects of these drugs are inevitable, including immunosuppression, gastrointestinal ulcers, osteoporosis, nausea, fatigue, cytopenia, rashes, liver damage, infections, and psoriasis. [479][480][481][482] Therefore, it is an urgent need to develop novel therapeutic strategies that enhance efficacy and reduce toxicity.…”

Section: Conclusion and Prospectsmentioning

confidence: 99%

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Ding

Wang

et al. 2023

Sig Transduct Target Ther

153

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease progression leads to joint deformity and associated loss of function, which significantly impacts the quality of life for sufferers and adds to losses in the labor force. In the past few decades, RA has attracted increased attention from researchers, the abnormal signaling pathways in RA are a very important research field in the diagnosis and treatment of RA, which provides important evidence for understanding this complex disease and developing novel RA-linked intervention targets. The current review intends to provide a comprehensive overview of RA, including a general introduction to the disease, historical events, epidemiology, risk factors, and pathological process, highlight the primary research progress of the disease and various signaling pathways and molecular mechanisms, including genetic factors, epigenetic factors, summarize the most recent developments in identifying novel signaling pathways in RA and new inhibitors for treating RA. therapeutic interventions including approved drugs, clinical drugs, pre-clinical drugs, and cutting-edge therapeutic technologies. These developments will hopefully drive progress in new strategically targeted therapies and hope to provide novel ideas for RA treatment options in the future.

show abstract

Section: Conclusion and Prospectsmentioning

confidence: 99%

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Ding

Wang

et al. 2023

Sig Transduct Target Ther

153

View full text Add to dashboard Cite

show abstract

“…However, the efficacy of drug treatment limited by the drug’s short effective half-life and its insufficient ability to specifically target diseased tissues, leading to poor clinical outcomes ( 5 ). Furthermore, upon in vivo administration, the drug is disseminated throughout the body, resulting in an elevated risk of side effects on extra-articular organs ( 6 ).…”

Section: Introductionmentioning

confidence: 99%

Natural biomimetic nano-system for drug delivery in the treatment of rheumatoid arthritis: a literature review of the last 5 years

Li,

Zhuang

2024

Front. Med.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized primarily by synovitis, leading to the destruction of articular cartilage and bone and ultimately resulting in joint deformity, loss of function, and a significant impact on patients’ quality of life. Currently, a combination of anti-rheumatic drugs, hormonal drugs, and biologics is used to mitigate disease progression. However, conventional drug therapy has limited bioavailability, and long-term use often leads to drug resistance and toxic side effects. Therefore, exploring new therapeutic approaches for RA is of great clinical importance. Nanodrug delivery systems offer promising solutions to overcome the limitations of conventional drugs. Among them, liposomes, the first nanodrug delivery system to be approved for clinical application and still widely studied, demonstrate the ability to enhance therapeutic efficacy with fewer adverse effects through passive or active targeting mechanisms. In this review, we provide a review of the research progress on the targeting mechanisms of various natural biomimetic nano-delivery systems in RA therapy. Additionally, we predict the development trends and application prospects of these systems, offering new directions for precision treatment of RA.

show abstract

“…the power wall. The power wall becomes more detrimental in advanced technology nodes due to several factors: (1) the introduction of Design Technology Co-Optimization (DTCO) around 20nm technology node has ensured that the transistor density keeps up with Moore's law projection, but power supply voltage scales much slower down the road thus making power density higher and higher from node to node, (2) to bridge the gap between processing capability and data availability due to Fig. 1: Data center electricity consumption breakdown in U.S. for the year 2014 [1].…”

Section: Introductionmentioning

confidence: 99%

“…A typical metric that measures the energy efficiency of data centers is Power Usage Efficiency (PUE) which is the total energy needed for everything, including cooling and lighting, divided by the energy used for IT equipments (a PUE of 1.0 is ideal). As per a recent data center survey report [2], the global average PUE in 2022 seems to saturate at 1.55 signifying ∼ 55% of total energy in a data center (on average) is now being expended on support infrastructure including cooling. In addition, it has sustainability challenges when it comes to their carbon footprints and CO 2 emissions.…”

Section: Introductionmentioning

confidence: 99%

Towards Chip-Package-System Co-optimization of Thermally-limited System-On-Chips (SOCs)

Mishra

Sankatali

Vermeersch

et al. 2023

2023 IEEE International Reliability Physics Symposium (IRPS)

View full text Add to dashboard Cite

Surge in compute-demand in consumer products, mobile phones, auto mobiles, datacenters for high performance computing (HPC) applications brings in major thermal challenges. This stems from growth in transistor density over the years and the associated power density increase. Advanced packaging techniques like 2.5D and 3D integration have a compounding effect. Hitting the thermal limits, not only affects the raw performance, power but also limits reliability of the product. Therefore, it has become necessary to foresee appropriate thermal solutions for target applications early in product development phase during thermal/power planning to assess viability of technology choices. In this paper, we assess the temperature distribution & anticipate cooling needs for future thermally-limited SOCs in advanced Angstrom nodes (A14 & A5). Thermal resistance breakdown from multiple sources is carried out to decouple contributions so as to explore possibility of a co-optimization of chip-package-cooling system. Some of the insights from our analysis could aid system software to do thermal aware job scheduling.

show abstract

The Patient Experience of Drug Side Effects in Rheumatoid Arthritis: Intriguing Data From an Exploratory Online Survey

Cited by 5 publications

References 22 publications

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Natural biomimetic nano-system for drug delivery in the treatment of rheumatoid arthritis: a literature review of the last 5 years

Towards Chip-Package-System Co-optimization of Thermally-limited System-On-Chips (SOCs)

Contact Info

Product

Resources

About